Proteome-Wide Effect of 17-beta-Estradiol and Lipoxin A(4) in an Endometriotic Epithelial Cell Line

Endometriosis affects approximately 10% of women of reproductive age. This chronic, gynecological inflammatory disease results in a decreased quality of life for patients, with the main symptoms including chronic pelvic pain and infertility. The steroid hormone 17-beta Estradiol (E2) plays a key role in the pathology. Our previous studies showed that the anti-inflammatory lipid Lipoxin A(4) (LXA(4)) acts as an estrogen receptor-alpha agonist in endometrial epithelial cells, inhibiting certain E2-mediated effects. LXA(4) also prevents the progression of endometriosis in a mouse model via anti-proliferative mechanisms and by impacting mediators downstream of ER signaling. The aim of the present study was therefore to examine global proteomic changes evoked by E2 and LXA(4) in endometriotic epithelial cells. E2 impacted a greater number of proteins in endometriotic epithelial cells than LXA(4). Interestingly, the combination of E2 and LXA(4) resulted in a reduced number of regulated proteins, with LXA(4) mediating a suppressive effect on E2-mediated signaling. These proteins are involved in diverse pathways of relevance to endometriosis pathology and metabolism, including mRNA translation, growth, proliferation, proteolysis, and immune responses. In summary, this study sheds light on novel pathways involved in endometriosis pathology and further understanding of signaling pathways activated by estrogenic molecules in endometriotic epithelial cells.

Published in:
Frontiers In Endocrinology, 6, 192
Lausanne, Frontiers Media Sa

 Record created 2016-07-19, last modified 2018-03-17

Rate this document:

Rate this document:
(Not yet reviewed)